Evidence map›Paper›PMID 28603416›Full record

ArticleInternational journal of nanomedicine2017

Successful in vivo hyperthermal therapy toward breast cancer by Chinese medicine shikonin-loaded thermosensitive micelle.

Yonghua Su, Nian Huang, Di Chen, Li Zhang, Xia Dong, Yun Sun, Xiandi Zhu, Fulei Zhang, Jie Gao, Ying Wang and 4 more

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Promising Nanomedicines of Shikonin for Cancer Therapy.International journal of nanomedicine · 2023
    Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 3 countries.

Yonghua SuDepartment of Integrative Oncology, Changhai Hospital of Traditional Chinese Medicine.
Nian HuangDepartment of Integrative Oncology, Changhai Hospital of Traditional Chinese Medicine.
Di ChenInternational Joint Cancer Institute, The Second Military Medical University, Shanghai.
Li ZhangInternational Joint Cancer Institute, The Second Military Medical University, Shanghai.
Xia DongInternational Joint Cancer Institute, The Second Military Medical University, Shanghai.
Yun SunInternational Joint Cancer Institute, The Second Military Medical University, Shanghai.
Xiandi ZhuInternational Joint Cancer Institute, The Second Military Medical University, Shanghai.
Fulei ZhangInternational Joint Cancer Institute, The Second Military Medical University, Shanghai.
Jie GaoInternational Joint Cancer Institute, The Second Military Medical University, Shanghai.
Ying WangInternational Joint Cancer Institute, The Second Military Medical University, Shanghai.
Kexing FanInternational Joint Cancer Institute, The Second Military Medical University, Shanghai.
Puichi LoDepartment of Biomedical Sciences, City University of Hong Kong, Kowloon Tong, Hong Kong, China.
Wei LiInternational Joint Cancer Institute, The Second Military Medical University, Shanghai.
Changquan LingDepartment of Integrative Oncology, Changhai Hospital of Traditional Chinese Medicine.
Second Military Medical University · CNLaboratoire d’immunologie intégrative du cancer · FRChanghai Hospital · CNCity University of Hong Kong · HK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Chinese traditional medicine Shikonin is an ideal drug due to its multiple targets to tumor cells. But in clinics, improving its aqueous solubility and tumor accumulation is still a challenge. Herein, a copolymer with tunable poly(N-isopropylacrymaide) and polylactic acid block lengths is designed, synthesized, and characterized in nuclear magnetic resonance. The corresponding thermosensitive nanomicelle (TN) with well-defined core-shell structure is then assembled in an aqueous solution. For promoting the therapeutic index, the physical-chemistry properties of TNs including narrow size, low critical micellar concentration, high serum stability, tunable volume phase transition temperature (VPTT), high drug-loading capacity, and temperature-controlled drug release are systematically investigated and regulated through the fine self-assembly. The shikonin is then entrapped in a degradable inner core resulting in a shikonin-loaded thermosensitive nanomicelle (STN) with a VPTT of ~40°C. Compared with small-molecular shikonin, the in vitro cellular internalization and cytotoxicity of STN against breast cancer cells (Michigan Cancer Foundation-7) are obviously enhanced. In addition, the therapeutic effect is further enhanced by the programmed cell death (PCD) specifically evoked by shikonin. Interestingly, both the proliferation inhibition and PCD are synergistically promoted as T > VPTT, namely the temperature-regulated passive targeting. Consequently, as intravenous injection is administered to the BALB/c nude mice bearing breast cancer, the intratumor accumulation of STNs is significantly increased as T > VPTT, which is regulated by the in-house developed heating device. The in vivo antitumor assays against breast cancer further confirm the synergistically enhanced therapeutic efficiency. The findings of this study indicate that STN is a potential effective nanoformulation in clinical cancer therapy.

Indexed as

AnimalsAntineoplastic AgentsBreast NeoplasmsDelayed-Action PreparationsDrugs, Chinese HerbalFemaleHumansHyperthermia, InducedMCF-7 CellsMice, Inbred BALB CMicellesNanostructuresNaphthoquinonesPolyestersPolymersSolubilityAntineoplastic AgentsDelayed-Action PreparationsDrugs, Chinese HerbalMicellesNaphthoquinonesPolyesterspoly(lactide)Polymersshikoninbreast cancercritical micelle concentrationhyperthermal therapyintra-tumor accumulationin vivoshikoninthermosensitive micelle

Identifiers

PMID28603416
PMCPMC5457155
OpenAlexW2619373126

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.